

NCI SBIR DEVELOPMENT CENTER

SBIR

SMALL BUSINESS INNOVATION RESEARCH

- Set-aside program to fund small business early stage R&D
- For small business concerns (SBC) that are organized as for-profit U.S.-based businesses with fewer than 500 employees
- SBC must do at least 2/3 of R&D work in Phase I, at least 1/2 in Phase II
- PI must be greater than 50% employed by SBC at time of award

STTR

SMALL BUSINESS TECHNOLOGY TRANSFER

- Basic SBC eligibility same as SBIR
- Formal cooperative R&D effort with a U.S. research institution
- SBC must do minimum of 40% of work; research institution must do minimum of 30% of work
- PI may be primarily employed by either SBC or research institution at time of award

BENEFITS

- Funding is non-dilutive and doesn't impact company stock
- Awards are not loans; no repayment is required
- Intellectual property rights retained by the small business
- Awards provide company recognition, verification, and visibility
- Projects vetted through NIH's rigorous scientific peer review
- Can be used as leverage to attract additional funding

GOALS

- Stimulate technological innovation
- Meet Federal R&D needs
- Foster and encourage participation in innovation and entrepreneurship by socially and economically disadvantaged persons
- Increase private-sector commercialization of innovations derived from Federal R&D funding




FY 23 SBIR / STTR FUNDING

\$1.3B at NIH

\$203M at NCI




WHAT ARE WE FUNDING?



We highly encourage applicants to chat with a program director prior to applying. To get started, send a one-page technology summary or your Specific Aims page to ncisbir@mail.nih.gov.

NCI SBIR FUNDING PHASES



SBIR

DEVELOPMENT CENTER

[HTTPS://SBIR.CANCER.GOV](https://sbir.cancer.gov)

NCI SBIR DEVELOPMENT CENTER

FUNDING OPPORTUNITIES

2023 Omnibus Solicitations | Investigator-initiated projects accepted in a broad range of areas supporting the mission of the institute.

- PA-23-230: SBIR, Clinical trial not allowed
- PA-23-231: SBIR, Clinical trial required
- PA-23-232: STTR, Clinical trial not allowed
- PA-23-233: STTR, Clinical trial required

Applications due January 5, 2024.

NCI SBIR Phase IIB Bridge Award | Post-Phase II award open to all SBIR/STTR Phase II Awardees from any Federal agency. Projects must address cancer.

- RFA-CA-23-034 | **Application closed.**

Contract Solicitation | The NCI announces a list of predefined topics for SBIR contract funding, covering a wide range of technology areas that fit the mission of the institute.

- PHS 2024-1 | **Applications due November 14, 2023.**

Commercialization Readiness Pilot (CRP) Program | Funding opportunity for previously funded SBIR/STTR Phase II and Phase IIB projects to facilitate transition to commercialization stage.

- PAR-23-129 | **Applications due January 5, 2024.**

NCI SBIR Concept Award | Funding opportunity for small businesses developing highly innovative therapies, diagnostic tools, or preventative strategies focused on pediatric and rare cancers.

Application closed.

Small Business Transition Grant | Designed to support early career academic scientists interested in transitioning to entrepreneurship while supporting transfer of technology from academic laboratories to small business.

- RFA-CA-23-035 | **Application closed.**

TARGETED FUNDING OPPORTUNITIES

Cancer Technologies for Low Resource Settings | Targeted funding for developing cancer technologies to improve outcomes in low- and middle-income countries and low-resource settings in the US.

- NOT-CA-21-062 | **Applications due January 5, 2024.**

Notice of Special Interest: Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | Targeted funding to develop technologies that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design.

- NOT-CA-23-004 | **Applications due January 5, 2024.**

Notice of Special Interest: SBIR Technology Transfer | Targeted funding to help move commercially-viable technologies from the NIH Intramural Program to the marketplace.

- NOT-NS-22-017 | **Applications due January 5, 2024.**

CONNECT WITH US!

@ Email: ncisbir@mail.nih.gov

☎ Phone: (240) 276-5300

✕ X: @NCISbir

in LinkedIn:

<http://bit.ly/NCISBIRLinkedIn>



<https://sbir.cancer.gov/aap>

Deadline information coming soon.

- Free resource aimed at helping eligible small businesses successfully apply for Phase I SBIR/STTR funding.
- Only small businesses that have not previously won an SBIR/STTR award from the NIH are eligible.



IS YOUR INVENTION
ENOUGH TO TURN IP
INTO IPO?

Get entrepreneurship training through I-Corps at NIH program.

<https://sbir.cancer.gov/icorps>

Applications due November 15, 2023.



If you would like to discuss your project with a NCI SBIR program director, send your Specific Aims page to ncisbir@mail.nih.gov at least one month before application receipt date.